Epalrestat Tablets
Formulation (FDF) · Tablets · 50mg
Formulation (FDF)Confidentiality：Public
- INN / Generic Name
- Epalrestat Tablets
- Dosage Form
- Tablets
- Strength
- 50mg
- Therapy Area
- Metabolic & Endocrinology
- Indication
- Diabetic peripheral neuropathy; Otitis media; Bronchitis; Pneumonia; Respiratory tract infection; Urinary tract infection; Skin and soft tissue infection; Bone infection; Joint infection; Septicaemia; Endocarditis infective; Hepatobiliary infection; Eye infection; Ear infection; Nasal infection; Throat infection; Surgical prophylaxis
- Current Status
- Official FDF licensing catalog (UB151)
- GMP Certification
- CN - NMPA
- CEP
- No
- DMF Type
- —
- Stability Data
- —
- BE Required
- Not required / waivable
- Registration Pathway
- Registered (market rights transferable / DCP·NP per market)
- MOQ
- On request
- Lead Time
- On request
- Price Range
- On request
HS Code
3004.903 customs bills on file
Registrable Markets
China
Process / Sequence / Exact Price
- Process Summary
- —
- Exact Price